Pelabresib (CPI-0610) Combined with Ruxolitinib for JAK Inhibitor Treatment-Naive Patients with Myelofibrosis: Durability of Response and Safety Beyond Week 24

被引：0

作者：

Mascarenhas, John ^{[1
]}

Kremyanskaya, Marina ^{[2
]}

Patriarca, Andrea ^{[3
,4
]}

Gupta, Vikas ^{[5
]}

Palandri, Francesca ^{[6
]}

Devos, Timothy ^{[7
,8
]}

Rampal, Raajit K. ^{[9
]}

Talpaz, Moshe ^{[10
]}

Vannucchi, Alessandro ^{[11
]}

Kuykendall, Andrew ^{[12
]}

Kiladjian, Jean-Jacques ^{[13
]}

Verstovsek, Srdan ^{[14
]}

Mesa, Ruben ^{[15
]}

Colak, Gozde ^{[16
]}

Li, Qing ^{[17
]}

Klein, Sandra ^{[16
]}

Harrison, Claire ^{[18
]}

机构：

[1] Icahn Sch Med Mt Sinai, Dept Hematol & Med Oncol, New York, NY 10029 USA

[2] Icahn Sch Med Mt Sinai, Tisch Canc Inst, Div Hematol & Med Oncol, New York, NY 10029 USA

[3] Univ Piemonte Orientale, Dept Translat Med, Hematol Unit, Novara, Italy

[4] AOU Maggiore Carite, Novara, Italy

[5] Univ Toronto, Dept Med, Toronto, ON, Canada

[6] IRCCS Azienda Osped Univ Bologna, Ist Ematol Seregnoli, Bologna, Italy

[7] Katholieke Univ Leuven, Univ Hosp Leuven, Leuven, Belgium

[8] Katholieke Univ Leuven, Rega Inst, Lab Mol Immunol, Leuven, Belgium

[9] Mem Sloan Kettering Canc Ctr, Ctr Hematol Malignancies, 1275 York Ave, New York, NY 10021 USA

[10] Univ Michigan, Comprehens Canc Ctr, Ann Arbor, MI 48109 USA

[11] Univ Florence, Azienda Osped Univ Careggi, Florence, Italy

[12] H Lee Mofitt Canc Ctr, Dept Malignant Hematol, Tampa, FL USA

[13] Univ Paris, Hop St Louis, Paris, France

[14] MD Anderson Canc Ctr, Houston, TX USA

[15] UT Hlth San Antonio MD Anderson Canc Ctr, Mays Canc Ctr, San Antonio, TX USA

[16] Constellat Pharmaceut Inc, Boston, MA USA

[17] MorphoSys US Inc, Boston, MA USA

[18] Guys & St Thomas NHS Fdn Trust, London, England

来源：

BLOOD | 2022年 / 140卷

关键词：

D O I：

10.1182/blood-2022-158147

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：4

共 50 条

[1] Pelabresib (CPI-0610) As Add-on to Ruxolitinib in Myelofibrosis: Durability of Response and Safety Beyond Week 24 in the Phase 2 MANIFEST Study
Harrison, Claire
Kremyanskaya, Marina
Bose, Prithviraj
Gupta, Vikas
Rampal, Raajit K.
Lambert, Jonathan
Talpaz, Moshe
Vannucchi, Alessandro
Kuykendall, Andrew
Kiladjian, Jean-Jacques
Verstovsek, Srdan
Mesa, Ruben
Colak, Gozde
Klein, Sandra
Dutta, Soumik
Mascarenhas, John
BLOOD, 2022, 140 : 9659 - 9662
[2] BET Inhibitor Pelabresib (CPI-0610) Combined With Ruxolitinib in Patients With Myelofibrosis - JAK Inhibitor-Naive or With Suboptimal Response to Ruxolitinib - Preliminary Data From the MANIFEST Study
Mascarenhas, John
Kremyanskaya, Marina
Patriarca, Andrea
Harrison, Claire
Bose, Prithviraj
Rampal, Raajit K.
Palandri, Francesca
Devos, Timothy
Passamonti, Francesco
Hobbs, Gabriela
Talpaz, Moshe
Vannucchi, Alessandro
Kiladjian, Jean-Jacques
Verstovsek, Srdan
Hoffman, Ron
Salama, Mohamed E.
Chen, Dong
Taverna, Pietro
Chang, Alex
Colak, Gozde
Klein, Sandra
Gupta, Vikas
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S335 - S336
[3] Clinical Benefit of Pelabresib (Cpi-0610) in Combination with Ruxolitinib in JAK Inhibitor Treatment-Naive Myelofibrosis Patients: Interim Efficacy Subgroup Analysis from Arm 3 of the MANIFEST Phase 2 Study
Gupta, Vikas
Kremyanskaya, Marina
Mascarenhas, John
Palandri, Francesca
Patriarca, Andrea
Devos, Timothy
Harrison, Claire
Passamonti, Francesco
Rampal, Raajit
Mead, Adam
Scandura, Joseph
Hobbs, Gabriela
Talpaz, Moshe
Granacher, Nikki
Somervaille, Tim
Hoffman, Ronald
Bose, Prithviraj
Colak, Gozde
Shao, James
Cui, Jike
Bobba, Suresh
Luptakova, Katarina
Verstovsek, Srdan
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S362 - S362
[4] Preliminary Report of MANIFEST, a Phase 2 Study of CPI-0610, a Bromodomain and Extraterminal Domain Inhibitor (BETi), in Combination with Ruxolitinib, in JAK Inhibitor (JAKi) Treatment Naive Myelofibrosis Patients
Harrison, Claire N.
Patriarca, Andrea
Mascarenhas, John
Kremyanskaya, Marina
Hoffman, Ronald
Schiller, Gary J.
Leber, Brian
Devos, Timothy
Kabir, Sujan
Senderowicz, Adrian
Mertz, Jennifer
Trojer, Patrick
Shao, James
Gupta, Vikas
BLOOD, 2019, 134
[5] MANIFEST: Pelabresib in Combination With Ruxolitinib for Janus Kinase Inhibitor Treatment-Naive Myelofibrosis
Mascarenhas, John
Kremyanskaya, Marina
Patriarca, Andrea
Palandri, Francesca
Devos, Timothy
Passamonti, Francesco
Rampal, Raajit K.
Mead, Adam J.
Hobbs, Gabriella
Scandura, Joseph M.
Talpaz, Moshe
Granacher, Nikki
Somervaille, Tim C. P.
Hoffman, Ronald
Wondergem, Marielle J.
Salama, Mohamed E.
Colak, Gozde
Cui, Jike
Kiladjian, Jean-Jacques
Vannucchi, Alessandro M.
Verstovsek, Srdan
Curto-Garcia, Natalia
Harrison, Claire
Gupta, Vikas
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (32) : 4993 - +
[6] Matching-Adjusted Indirect Comparison (MAIC) of Pelabresib (CPI-0610) in Combination With Ruxolitinib vs. JAK Inhibitor Monotherapy in Patients With Intermediate or High-Risk Myelofibrosis
Gupta, Vikas
Mascarenhas, John
Kremyanskaya, Marina
Rampal, Raajit K.
Talpaz, Moshe
Kiladjian, Jean-Jacques
Vannucchi, Alessandro
Verstovsek, Srdan
Colak, Gozde
Dey, Debarshi
Harrison, Claire
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S336 - S336
[7] CPI-0610, A BROMODOMAIN AND EXTRATERMINAL DOMAIN (BET) PROTEIN INHIBITOR, IN COMBINATION WITH RUXOLITINIB, IN JAK INHIBITOR-NAIVE MYELOFIBROSIS PATIENTS: UPDATE OF MANIFEST PHASE 2 STUDY
Palandri, F.
Mascarenhas, J.
Harrison, C.
Patriarca, A.
Devos, T.
Rampal, R.
Vannucchi, A.
Passamonti, F.
Mead, A.
Kremyanskaya, M.
Somervaille, T.
Wondergem, M.
Hoffman, R.
Luptakova, K.
Wang, J.
Colak, G.
Shao, J.
Bobba, S.
Trojer, P.
Verstovsek, S.
Gupta, V.
HAEMATOLOGICA, 2021, 106 (10) : 5 - 6
[8] CPI-0610, a bromodomain and extraterminal domain (BET) protein inhibitor, in combination with ruxolitinib, in JAK-inhibitor-naive myelofibrosis patients: Update of MANIFEST phase 2 study
Platzbecker, U.
Mascarenhas, J.
Harrison, C.
Patriarca, A.
Devos, T.
Palandri, F.
Rampal, R.
Vannucchi, A.
Mead, A.
Kremyanskaya, M.
Somervaille, T.
Wondergem, M.
Hoffman, R.
Luptakova, K.
Wang, J.
Colak, G.
Shao, J.
Bobba, S.
Trojer, P.
Verstovsek, S.
Gupta, V
ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 158 - 158
[9] CPI-0610, a bromodomain and extraterminal domain protein (bet) inhibitor, in combination with ruxolitinib, in jak-inhibitor-naive myelofibrosis patients: update of manifest phase 2 study
Mead, Adam
Mascarenhas, John
Talpaz, Moshe
Patriarca, Andrea
Devos, Timothy
Palandri, Francesca
Passamonti, Francesco
Rampal, Raajit
Kremyanskaya, Marina
Scandura, Joseph
Somervaille, Tim
Wondergem, Marielle
Granacher, Nikki
Hoffman, Ronald
Gupta, Vikas
Luptakova, Katarina
Wang, Jing
Christo, Jessica
Colak, Gozde
Shao, James
Bobba, Suresh
Trojer, Patrick
Verstovsek, Srdan
Harrison, Claire
BRITISH JOURNAL OF HAEMATOLOGY, 2021, 193 : 96 - 96
[10] Phase III MANIFEST-2: pelabresib plus ruxolitinib vs placebo plus ruxolitinib in JAK inhibitor treatment-naive myelofibrosis
Harrison, Claire N.
Gupta, Vikas K.
Gerds, Aaron T.
Rampal, Raajit
Verstovsek, Srdan
Talpaz, Moshe
Kiladjian, Jean-Jacques
Mesa, Ruben
Kuykendall, Andrew T.
Vannucchi, Alessandro M.
Palandri, Francesca
Grosicki, Sebastian
Devos, Timothy
Jourdan, Eric
Wondergem, Marielle J.
Al-Ali, Haifa Kathrin
Buxhofer-Ausch, Veronika
Alvarez-Larran, Alberto
Patriarca, Andrea
Kremyanskaya, Marina
Mead, Adam J.
Akhani, Sanjay
Sheikine, Yuri
Colak, Gozde
Mascarenhas, John
FUTURE ONCOLOGY, 2022, 18 (27) : 2987 - 2997

← 1 2 3 4 5 →